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Abstract. The lymphocyte-high endothelial venule
(HEV) cell interaction is an essential element of the
immune system, as it controls lymphocyte recirculation
between blood and lymphoid organs in the body. This
interaction involves an 85-95-kD class of lymphocyte
surface glycoprotein(s), CD44. A subset of lympho-
cyte CD44 molecules is modified by covalent linkage
to chondroitin sulfate (Jalkanen, S., M. Jalkanen, R.
Bargatze, M. Tammi, and E. C. Butcher. 1988. J. Im-
munol. 141:1615-1623). In this work, we show that
removal of chondroitin sulfate by chondroitinase treat-
ment of lymphocytes or incubation of HEV with chon-
droitin sulfate does not significantly inhibit lymphocyte
binding to HEV, suggesting that chondroitin sulfate is
not involved in endothelial cell recognition of lympho-
cytes. Affinity-purified CD44 antigen was, on the other
hand, observed to bind native Type I collagen fibrils,
laminin, and fibronectin, but not gelatin. Binding to
fibronectin was studied more closely, and it was found
to be mediated through the chondroitin sulfate-contain-
ing form of the molecule. The binding site on fibronec-
HERMEs-defined humanlymphocyte surface molecules
were originally designated as lymphocyte homing
receptors because of their involvement in lympho-
cyte binding to organ-specific endothelial cell determinants
in lymphoid organs (Jalkanen et al., 1986; Jalkanen, S. et
al., 1987). Recently, the antigen recognized by the Hermes
series of mAbs has been shown to be identical to, or include,
the CD44 antigen (Picker et al., 1989a; Goldstein et al.,
1989; Stamenkovic et al., 1989). ExpressionofCD44 or an-
tigenically related proteins is not restricted to lymphocytes
(Jalkanen et al ., 1986; Picker et al., 1989a,b). Other leuko-
cytes as well as some nonhematopoietic cell types express
CD44 molecules of various sizes (Picker et al., 1989b; Pals
et al., 1989). CD44 molecules on different cell types seem
to have different functions. For example, CD44 antigen (90
kD) from lymphoma cells is able to bind to purified mucosal
endothelial cell ligand, addressin, whereas CD44 antigen
(150 kD) from epithelial cells lacks such binding capability
(Berget al., 1989; Picker et al., 1989b). CD44 has also been
described to be involved in T cell activation (Shimizu et al.,
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tin was the COOH-terminal heparin binding domain,
because (a) the COOH-terminal heparin-binding frag-
ment of fibronectin-bound isolated CD44 antigen; (b)
chondroitin sulfate inhibited this binding; and (c)
finally, the ectodomain of another cell surface proteo-
glycan, syndecan, which is known to bind the 000H-
terminal heparin binding domain of fibronectin (Saun-
ders, S., and M. Bernfield. 1988. J. Cell BlOI. 106:
423-430), inhibited binding of CD44 both to intact
fibronectin and to its heparin binding domain. More-
over, inhibition studies showed that binding of a lym-
phoblastoid cell line, KCA, to heparin binding pep-
tides from COOH-terminal heparin binding fragment
of fibronectin was mediated via CD44. These findings
suggest that recirculating lymphocytes use the CD44
class of molecules not only for binding to HEV at the
site of lymphocyte entry to lymphoid organs as reported
earlier but also within the lymphatic tissue where
CD44, especially the subset modified by chondroitin
sulfate, is used for interaction with extracellular matrix
molecules such as fibronectin.
1989; Huet et al ., 1989), lateral movement of cells(Jacobson
et al ., 1984), and erythrocyte rosetting (Hale et al., 1989) .
Furthermore, Carter and Wayner (1988) have shown that
fibroblast CD44 (extracellular matrix receptor III) binds to
collagen and fibronectin, and colocalizes with vimentin. In
another study (Kalomiris and Bourguignon, 1988), binding
of CD44 to a cytoskeletal protein ankyrin has been demon-
strated. These findings suggest that CD44 may link adhesive
interactions at cell surface with the cytoskeleton. Recently,
CD44 has been shown to function also as a hyaluronate
receptor (Aruffo et al., 1990; Miyake et al., 1990). These
examples clearly demonstrate the multifunctional character-
istics of CD44.
Structurally CD44 molecules belong to the family of pro-
teoglycans, since in addition to0-linkedand N-linkedcarbo-
hydrates, a subset of lymphocyte CD44 molecules contains
chondroitin sulfate side chains yielding a higher molecular
mass form of 180-200 kD (Jalkanen et al., 1988) . Moreover,
CD44 is expressed on epithelial cells with heparan sulfate
side chains (Brown et al., 1991). Recent sequence data in-
817dicate that CD44 has significant homology to functional
domains in the cartilage link protein andthe cartilage proteo-
glycan monomer; and despite striking biochemical similari-
ties, it is unrelated to mouse peripheral lymph node homing
receptor (MEL-14) (Goldstein et al., 1989 ; Stamenkovic et
al., 1989; Siegelman et al., 1989; Lasky et al., 1989) . Fur-
thermore, new variants of CD44 mainly expressed on cells
of epithelial origin have been sequenced (Brown et al., 1991;
Giinthert et al., 1991; Stamenkovic et al., 1991), but the
functional roles ofthe variant are still unclear. Interestingly,
one variant has been connected to metastatic behavior of rat
carcinoma cells (Giinthert et al., 1991). Thus, CD44 repre-
sents a polymorphic family of cell adhesion molecules.
Since cell surface proteoglycans are important in diverse
cell-cell and cell-matrix adhesive interactions (Ruoslahti,
1988, 1989), this work was designed to study the role of
chondroitin sulfate on lymphocyte CD44 antigen. Our
results indicate that chondroitin sulfate is not needed for
lymphocyte-high endothelial venule (HEV)' interaction .
However, the ability ofthe CD44 antigen to bind extracellu-
lar matrix molecules, especially fibronectin, via chondroitin
sulfate chains suggests that the high molecular weight form
of CD44 could, indeed, be involved in lymphocyte-matrix
interaction subsequentto lymphocyte extravasation into tis-
sues. By this mechanism CD44 might participate at the tis-
sue level in lymphocyte migration, differentiation and matu-
ration.
Materials andMethods
Cells
Ficoll- (Ficoll-Paque, Pharmacia Fine Chemicals, Piscataway, NJ) purified
human peripheral blood lymphocytes (PBLs) from normal healthy adults
were used in the HEV assays. The PBL from leukopheresis samples ofpa-
tients suffering from rheumatoid arthritis were used for CD44 antigen isola-
tion. This source was selected because it allowed relatively large quantities
ofCD44 to be isolated. Composition of90-kD and 180-kD forms ofCD44
on PBL of these patients did not differ from that seen on PBL of healthy
individuals when tested using immunoblotting. A lymphoblastoid B cell
line, KCA, that was used in binding assays to fibronectin and fibronectin
peptides was a generous gift from Dr. E. Engleman (Stanford University,
Stanford, CA) .
Antibodies
Production and specificity of polyclonal anti-CD44 and mAbs, Hermes-1
and Hermes-3, against distinct epitopes of CD44 have been described ear-
lier (Jalkanen et al., 1986; Jalkanen, S., et al., 1987). Hermes-1 inhibits
hyaluronate binding to CD44, whereas Hermes-3 is able to block lympho-
cytebinding to mucosal HEV (Culty et al., 1990; Jalkanen, S., etal., 1987).
For inhibition studies Hermes-1 and Hermes-3 mAbs were used as serum-
free culture supernatants and polyclonal mouse anti-CD44 (that inhibits
lymphocyte binding to peripheral lymph node, mucosal and synovial HEV;
Jalkanen, S., et al., 1987) at 1:10 dilution. A polyclonal rabbit antibody
against the common human 0 (01) chain of VLA-integrins was a generous
gift from Dr. J. Heino (Turku University, Turku, Finland) and was used at
1:50 dilution. mAb against thealfa chain of VLAA (HP2/1) was a generous
gift from Dr. F Sanchez-Madrid (University of Madrid, Madrid, Spain),
and mAb against the alfachain ofVLA-5 was from Immunotech, Marseille,
France. mAb 3E1 against the COOH-terminal heparin-binding domain of
fibronectin was from Boehringer Mannheim Biochemicals (Indianapolis,
IN). Specificity of this antibody has been reported by Pierschbacher et al.
(1981). Anti-CD3 from American Type Culture Collection (Rockville, ML)
and 281.2 against syndecan (Jalkanen et al., 1985) were used as class-
1. Abbreviations used in this paper: HEV, high endothelial venule; PBL,
peripheral blood lymphocytes.
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matched negative control antibodies, and 281.2 was also used for syndecan
purification. Normal mouse serum and normal rabbit serum were used as
controls for polyclonal antisera. The second stage reagent for ELISA was
alkaline phosphatase-conjugated goat anti-mouse IgG and IgM (Tago Inc.,
Burlingame, CA), for immunoblotting peroxidase-conjugated rabbit anti-
mouse Ig (Dako Corp., Santa Barbara, CA) and for immunofluorescence
FITC-conjugated sheep anti-mouse IgG (Sigma Chemical Co., St. Louis,
MO) and FITC-conjugated goat anti-rabbit IgG (Sigma Chemical Co.) .
Immunofluorescence
Single color indirect immunofluorescence was carried out as described
(Jalkanen et al., 1986) using saturating levels of the first-stage antibodies
followed by the appropriate second-stage reagent, either FTTC-conjugated
sheep anti-mouse IgG (Sigma Chemical Co.) or FIX-conjugated goat
anti-rabbit IgG (Sigma Chemical Co.). Samples were analyzed using a
cytometer (FACScan, Becton-Dickinson Immunocytometry Sys., Moun-
tain View, CA) . Routinely, data from 10,000 cells were collected.
Chondroitinase Treatment
For chondroitinase treatment human PBL (1.8 x 107) and KCA (4.5 x
106; KCA cells are approximately four times the size of PBL cells) were
incubated for 2 h at 37°C with 0.25 U ofchondroitinase ABC (Miles-Yeda,
Elkhart, IN) in 1 ml RPMI 1640 medium containing 1% BSA and 10 mM
Hepes. Control lymphocytes were maintained in the same conditions with-
out chondroitinase. This treatment was sufficient to remove all the high mo-
lecular weight form of the CD44 antigen, as determined by SDS-PAGE of
immunoisolated CD44 from sulfate-labeled lymphocytes (not shown).
In Vitro Frozen Section Assay
An in vitro frozen section assay was performed as described earlier
(Stamper and Woodruff, 1976; Jalkanen and Butcher, 1985). Briefly, lym-
phocytes in RPMI 1640 containing 5% FCS and 10 mM Hepes, pH 7.3,
were incubated on fresh gut frozen sections ofhuman and mouse peripheral
lymph nodes, human appendix, mouse Peyees patches, and human inflamed
synovium for 30 min at 7°C. Similar results were obtained both on mouse
and human HEV. The preservation of tissue specificity in xenogeneic lym-
phocyte-HEV interactionshas been previously described (Wuet al., 1988).
After incubation, boundlymphocytes were fixed incold PBS containing 1%
glutaraldehyde, and cell binding was quantitated microscopically as de-
scribed earlier (Jalkanen and Butcher, 1985). Approximately 130 HEV per
sample were counted. In other sets of experiments, either 100 Pl (100
,ug/ml) chondroitin sulfate (Sigma Chemical Co.) or heparan sulfate (Sigma
Chemical Co.)or PBS (control) was incubatedon frozen sections for 30min
at 7°C before the assay. Thereafter, untreatedPBL were addedandthe bind-
ing assay was performed in a standard way. Results are presentedas relative
adherence ratios, the calculated number ofsample cells bound to HEV per
control cell binding under identical conditions. Standard errors were deter-
mined by the delta method (Rao, 1965).
Purification ofCD44 and Syndecan Ectodomain
Lymphocytes were lysed in lysis buffer (1% NP-40, 0.15 M NaCl, 0.01 M
Tris, pH 7.0, 1.5 MM M9C12, and 1 mM PMSF). The clarified lysate was
applied first to a Sepharose CL-4B (Pharmacia Fine Chemicals) column
(30-mlcolumn volume) and then sequentially to two CnBr-activated Sepha-
rose-4B (Pharmacia FineChemicals) columns, derivatized respectivelywith
normal rat serumand with Hermes-1 mAb (5 mg/ml, 3 ml column volume) .
The column was washed extensively with the lysis buffer. Thereafter, the
material boundto the Hermes-1 column was elutedwith 50 mM triethanola-
mine and lyophilized. Fractionation ofdifferent forms of the CD44 antigen
was performed using the Elfe fractionation system (Genofit; Grand Lancy,
Switzerland). Purity ofisolated CD44 was analyzedby protein staining af-
ter SDS-PAGEand also by inununoblotting. Small amounts ofHermes-1 an-
tibody eluted offthe columnwith CD44, and was the contaminating protein
in somepreparations. Ifthe purity was not satisfactory (othervisible protein
bands), the affinity binding with the subsequent steps was repeated. After
gel fractionation (Elfe, Genofit) no proteins other than CD44 were ob-
served.
The ectodomain ofthe cell surface proteoglycan (syndecan; Saunders et
al., 1989) was prepared from conditioned culture medium of NMuMG
mouse mammary epithelial cells by DEAF chromatography, CsC12 density
centrifugation, and 281.2 mAb affinity chromatography, as has been de-
scribed elsewhere (Jalkanen et al., 1985; Jalkanen, M., et al., 1987).
818Enzymatic DigestionofFIbronectin
Fibronectin (1 mg/ml) in 2.5 MM CaC12, 0.5 mM EDTA, 50 mM NaCl,
and 25 mM Tris/HCI (pH 7.2) was digested for 4 h at 22°C with 5 pg/ml
of thermolysin (Protease X; Sigma Chemical Co.).
SyntheticPeptides
Two peptides (YEKPGSPPREVVPRPRPGV and KNNQKSEPLIGRKKT;
residues 1,906-1,924 and 1,946-1,960, respectively) known to promote
heparin binding to COOH-terminal heparin-binding domain of fibronectin
(McCarthy et al., 1988) were synthesized using an automated peptide syn-
thesizer (model 431A; Applied Biosystems Inc., Foster City, CA). In addi-
tion, negative controlpeptides, CSI (DELPQLVTLPHPNLHGPEII.DVPSr),
from the COOH-terminal region offibronectin knowntocontain the binding
site for VLA-4 but not to promote the heparin binding and RGDS were like-
wise synthesized. Purificationofpeptides wascarriedoutwith apreparative
HPLC (Applied Biosystems Inc.) using a reversed phase column, and their
purity was confirmed by an analytical HPLC (Applied Biosystems Inc.) .
BindingofPurified CD44 to Matrix Molecules
Binding ofthe purified CD44 antigen to fibronectin, laminin, collagen type
I fibrils, and gelatin was tested using an ELISA method. Polystyrene plates
(M129B; Dynatech Laboratories, Inc., Alexandria, VA) were coated over-
night at 37°C with the indicated amountof gelatin (Merck & Co. Inc., Rah-
way, NJ), of human fibronectin (Calbiochem-Behring Corp., San Diego,
CA), of-COOH-terminal heparin-binding fragment of fibronectin (Calbio-
chem-Behring Corp.), of laminin (Sigma Chemical Co.), of collagen type
I fibrils (purified using a previously describedmethod; Chandrahasan etal.,
1976), or fibronectin peptides. Thereafter, the wells were washed free of
unbound material and saturated with 1% gelatin for 2 h. Approximately
5 ng (in PBS) ofpurifiedCD44 antigen was appliedto the wells. Afterover-
night incubation unbound material was washed away with PBS containing
0.5% 'Itveen-20. Bound material was detected using Hermes-3 mAb as a
first stage antibody, and alkaline phosphatase conjugated goat anti-mouse
IgG and IgM (Tago Inc.) was used at the second stage. mAb against CD3,
CRL8001 (American Type Culture Collection), served as a class matched
negative control antibody. Whentheinhibitionassays wereperformed, hepa-
rin (Sigma Chemical Co.), heparin sulfate (Sigma Chemical Co.), chon-
droitin sulfate (Sigma Chemical Co.). synthetic RGDS peptide (negative
control), isolated ectodomain of syndecan, mannan (negative control;
Sigma Chemical Co.), or soluble fibronectin (Calbiochem-Behring Corp.)
was added after nonspecific binding sites had been blocked with gelatin.
The wells were then incubated for 1 h at 37°C before the purified CD44
antigen was applied. The experiments were performed using triplicate
wells.
Lymphocyte CD44 antigen binding to intact fibronectin and fibronectin
fragments wasmeasuredalsousing immunoblottingmethod. Intact fibronec-
tin, COOH-terminal heparin-binding domain of fibronectin (Calbiochem-
Behring Corp.), and thermolysin digested fibronectin fragments (30 kg)
were loaded, after reduction with 2 % mercaptoethanol, onto agradient (5-
17.5%) SDS-PAGE. Phosphorylase b, 94 kD; BSA, 67 kD; ovalbumin, 43
kD; carbonic anhydrase, 30 kD; soybean trypsin inhibitor, 20.1 kD; lactal-
bumin, 14.4 kD served as molecular mass standards and asnegative control
proteins for the binding experiments. Proteins in the gel were transferred
onto a nitrocellulose paper, and nonspecific binding sitesonthe paper were
blockedwith PBS containing 0.1% Tween-20. The nitrocellulose strips were
then incubated overnight with affinity-purified CD44 antigen in PBS. The
bound antigen was detected with Hermes-3 mAb using peroxidase-conju-
gated rabbit anti-mouse Ig (DakoCorp.) at the second stage, with 4-chloro-
1-naphtol (Sigma Chemical Co.) as the substrate. Monoclonal anti-CD3 an-
tibody served as a negative control antibody. Fragments of COOH-terminal
heparin-binding domain of fibronectin were detected using a mAb, 3E1
(Boehringer Mannheim Biochemicals), that recognizes this domainof fibro-
nectin.
BindingofCells to Nbronectin
andFfbronectin Peptides
Glassslides withtissue culture chambers (LabTek Div., Miles Laboratories
Inc., Naperville, IL) were coated with fibronectin and fibronectin peptides
(101ig/ml) overnightat 37°C and then blocked with 1 tng/ml heat-denatured
BSA in PBS for 1 h at 37°C. KCA cells (150,000/well in HB101 serum-free
medium; Du Pont, Hana Biologics, Inc., Alameda, CA) were addedand al-
lowed to adhere for 2 h at 37°C. Inhibition assays were performed in the
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presence ofchondroitin sulfate, heparin, and affinity-purified CD44. When
the inhibitory capacity of different antibodies (Hermes-1, Hermes-3, poly-
clonal anti-CD44, andanti-Sl and their negative controls) was tested, KCA
cells were first treated with the antibodies for30 min and then washedonce
before the assay, oralternatively, the assays were performed in the presence
ofthe antibodies. After incubation, unattached cells were removed by flick-
ing. The tops ofthe wells were removed and the slides were washed by dip-
ping them in PBS. Bound cells were fixed with 1% formaldehyde in PBS.
Thereafter, the cells were stained using the Dif Quick stains (comparable
to May-Griinwald-Giemsa; Merz+Dade AG, Dudingen, Switzerland) and
mounted in DePex (BDH Chemicals Ltd., Poole, England). The number of
bound cells were analyzed by counting at least 20 fields in each case using
an oculargrid (at a magnification of250). Each experiment was performed
using duplicate wells.
Results
Chondroitin Sulfate MoietiesAreNotInvolved
in Lymphocyte-HEV Interaction
Possible involvement of chondroitin sulfate in lympho-
cyte-HEV interaction was investigated using an in vitro fro-
zen section assay (Stamper and Woodruff, 1976; Jalkanen
and Butcher, 1985). First, lymphocytes were treated with
chondroitinase to cleave chondroitin sulfate side chains from
the CD44 molecule. The conditions of this enzymatic treat-
ment had been tested and previously determined to be
sufficient to cleave chondroitin sulfate side chains of the
CD44 antigen from intact lymphocytes. Such treatment had
no effect on lymphocyte binding to peripheral lymph node,
mucosal, or synovial HEV (Fig. 1). To confirm this finding,
frozen sections were treated with chondroitin sulfate and
heparan sulfate before the assay. The potential inhibitors
were also present in the incubation medium during the assay.
These conditions resulted in decreased binding, but the de-
crease did not achieve statistical significance (Fig. 1). In con-
trast, a polyclonal anti-Hermes antibody (anti-gp90; Jalka-
nen, S. et al., 1987) inhibits nearly 90% of lymphocyte
binding to HEV (data not shown) . Based on these results,
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Figure 1. Chondroitin sulfate side chains play no significant role in
lymphocyte-HEV interaction. In vitro frozen section binding as-
says were done four times on peripheral lymph nodes and mucosa-
associated lymphatic tissues, and twice on inflamed (rheumatoid)
synovial tissue. Data from those experiments are pooled.Figure 2. Binding of purified
lymphocyte CD44 antigen to
extracellular matrix molecules.
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chondroitin sulfate seemingly plays no significant role in
lymphocyte binding to their HEV ligands.
CapacityofLymphocyte CD44Antigen
to BindExtracellularMatrix Molecules
An ELISAwas established to test the capacity oflymphocyte
CD44 antigen to bind surfaces coated with matrix mole-
cules. In this assay, microtiter wells were first coated with
fibronectin, laminin, collagen Type I fibrils, or gelatin. Then
the purified CD44 was added and the immobilized CD44
was detected with primary and secondary antibodies. In this
assay, purified CD44 antigen bound to fibronectin, laminin,
and collagen type I, but not to denatured collagen (gelatin)
(Fig. 2). Next, CD44 binding to fibronectin was studied
more closely. When 2 pg/ml offibronectin was used for coat-
ing, the saturation level was achieved with -1 ng of CD44
antigen per well. When, however, 100 ug/m1 of fibronectin
was used, saturation was not observed, even though the
amount of CD44 antigen applied was increased to 5 ng/well.
The titration curves of CD44 antigen binding to fibronectin
in ELISA are shown in Fig. 3. These saturation curves
clearly indicate the concentration dependency of this assay,
both for the added CD44 antigen and for the binding sites
on fibronectin-coated wells.
Binding of CD44 antigen to fibronectin was confirmed by
immunoblotting : CD44 antigen bound to fibronectin trans-
ferred from the SDS-PAGE to nitrocellulose, whereas no
binding of CD44 was observed to any ofthe control proteins
(Fig. 4 A). Binding sites on fibronectin were studied after
1500
1000
500
Hermes antigen (ng)
Figure 3. Binding ofpurified lymphocyte CD44 antigen to fibronec-
tin. Fibronectin (Fn) at the indicated amount was used as a ligand
for coating. Binding was measured using an ELISA assay, as de-
scribed in Materials and Methods. Absorbance values are
presented as net absorbance values, as in Fig. 2.
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thermolysin digestion that generates well-defined fragments
from intact fibronectin molecule (Sekiguchi and Hakomori,
1983; Zardiet al ., 1985) . Purified CD44 antigen reproduci-
bly bound to a 29-kD fragment that is described to be one
of the heparin-binding domains offibronectin (Fig. 4 A, lane
f) . Very weak binding was sometimes observed to other
fragments, perhaps representing partial digestion products
containing still the heparin-binding domain. Since both
NHZ-terminal and COOH-terminal heparin-binding frag-
ments after thermolysin digestion are at the same molecular
mass range (28-29 kD), we tested the binding to commer-
cially available COOH-terminal heparin-binding domain of
fibronectin (Chymotrypsin digested) . The CD44 antigen
bound to the fragments of COON-terminal heparin-binding
domain as shown in Fig. 4 B. The origin of the fragments
was confirmed by using 3E1 antibody that recognizes an epi-
tope which is located at the COOH-terminal heparin-binding
site offibronectin (Fig. 4 B). The original size ofchymotryp-
sin digested COOH-terminal heparin-binding domain is 40
kD. The smaller fragments seen in Fig. 4B are most likely
degradation products of this larger fragment. This opinion
is supported by the result that the 3E1 antibody recognized
the smaller fragments, too.
McCarthy et al. (1988) have reported two peptides with
heparin-binding activitiesfrom the COON-terminalheparin-
binding domain of fibronectin. Binding to the COOH-termi-
nal heparin-binding domain of fibronectin was further con-
firmed by the experiments in which these heparin-binding
peptides were used for coating (100 pg/ml). CSI peptide
served as a negative control peptide. As reported below, the
absorbance values given represent net absorbances: they
were derived by subtractingthose absorbancevaluesobtained
from the CD44 binding to the CSI control peptide from those
of CD44 binding to YEKPGSPPREVVPRPRPGV or to
KNNQKSEPLIGRKKT. Mean absorbance values with their
standard errors oftwo experiments are given. CD44 showed
weak but clearly over the background binding (net absor-
bance 175 f 64) to YEKPGSPPREVVPRPRPGV. Binding
of CD44 was significant to KNNQKSEPLIGRKKT (net ab-
sorbance 440 t 148; P < 0.01). The CD44 binding to KNN-
QKSEPLIGRKKT represented 65.5% of the binding to in-
tact fibronectin. The sum of these absorbance values was
close to the value obtained from the binding to intact fibro-
nectin in these particular experiments (91.5 %), indicating
that CD44 can bind to more than one polypeptide region.
Chondroitin Sulfate ContainingForm oftheCD44
Molecule IsResponsibleforBindingtoFlbronectin
When the CD44 antigen was fractionated into its 90- and
180-200-kD forms (Fig. 5), only the form containing chon-
droitin sulfate was capable ofbinding to fibronectin (Fig. 5) .
The ELISA absorbance values are presented from an experi-
ment in which one-sixth of the material shown in both lanes
was applied to each microwell. Neither aggregation nor
oversaturation accounted for the lack of binding of the mate-
rial in lane 1, since, in fact, decreasing the amount ofthe ma-
terial applied did not increase the binding (data not shown).
Involvement of chondroitin sulfate moieties was further
tested in inhibition studies. In the ELISA system, heparin,
heparan sulfate, and chondroitin sulfate inhibited binding of
CD44 antigen to fibronectin in a dose-dependent manner.
Maximum inhibition of 53 % was observed at the level of 50
820pg/ml (Fig . 6) . However, the ectodomain of a cell surface
proteoglycan, syndecan, that binds to the COOH-terminal
heparin-binding domain of fibronectin via its heparan sulfate
side chains (Saunders and Bernfield, 1988) inhibited the
binding more efficiently. Inhibition varied somewhat, de-
pending on the experiment, from 85 to 98% at syndecan ec-
todomain concentration of 50 jg/ml (Fig . 6) . At a 0.5-Ag/ml
concentration, no significant inhibition was seen . When the
heparin-binding domain offibronectin was used in this assay,
inhibition by syndecan ectodomain was likewise almost
complete (Table I) . These data indicate that chondroitin sul-
fate side chains are involved in mediating the CD44 antigen
binding to fibronectin and, moreover, that the binding site is
the same as (or very near to) that of heparin and heparan sul-
fate. Soluble form of fibronectin did not significantly inhibit
the binding (Fig . 6) . Further, no binding inhibition was ob-
served with mannan, which has been shown to inhibit lym-
phocyte binding to HEV in peripheral lymph nodes (Stool-
man et al ., 1984) .
CD44 MediatesLymphocyte Binding to Fibronectin
Involvement of CD44 in lymphocyte binding to fibronectin
was tested using a cell line, KCA, that expresses VLA5,
known to mediate binding to the RGD-containing central
cell-binding domain (Pytela et al., 1985), and VLA-4,
known to mediate binding to CSI peptide (Wayner et al .,
1989 ; Guan and Hynes, 1990) . In contrast to low/moderate
fluorescence intensity obtained with antibodies against alfa
chains ofVLA-4 and VLA-5, KCA cells were brightly posi-
tive with Hermes-3 mAb (Fig . 7) . This cell line also ex-
pressed significant amount of the chondroitin sulfate-con-
taining form ofCD44 when tested in immunoblotting after
SDS-PAGE (data not shown) . In normal culture conditions,
KCA cells form small clusters and grow in suspension . How-
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Figure 4. CD44 antigen binds to the heparin-binding
domain offibronectin . (A) Amidoblack staining of mo-
lecular weight markers (lane a), intact fibronectin (lane
b), and fibronectin fragments after thermolysin treat-
ment (lane c) . PurifiedCD44 antigen was incubated on
intact fibronectin (lanes d and e), on thermolysin-
digested fibronectin (lanesfand g), and on molecular
weight markers as control proteins (lanes h and i) after
which the bound antigen has been detected either with
monoclonal Hermes-3 antibody panes d, f, and h) or
negative control antibody anti-CD3 panes e, g, and i) .
(B) Purified CD44 antigen was incubated on 000H-
terminal heparin-binding fragments of fibronectin .
Bound antigen was detected either with Hermes-3 anti-
body pane a), or with the negative control antibody,
anti-CD3 (lane b) . Origin of the fragments was
confirmed (lane c) by using mAb against 000H-
terminal heparin-binding domain of fibronectin .
ever, when plated on fibronectin-coated surfaces they ad-
hered efficiently and showed fairly extensive spreading and
formation of pseudopodia . They also adhered to peptides
that mediate heparin binding as well as to CSI and RGDS .
However, the peptides supported only minimal spreading . In
mild washing conditions the number of cells bound per unit
area (1.5 mm') was approximately the same to all these
peptides used and to fibronectin . However, more vigorous
washing conditions showed that binding to fibronectin was
more efficient than to any of the peptides alone . Number of
cells bound per unit area was practically unchanged in these
washing conditions when fibronectin (443 f 7 cells bound
per unit area) was used for coating, whereas less cells ad-
hered to peptides (PI = KNNQKSEPLIGRKKT, 230 t 39 ;
PII = YEKPGSPPREVVPRPRPGV, 152 f 14 ; PHI = CSI,
314 f 4, binding to RGDS was not studied systemically) .
Binding to BSA that was used as a negative control protein
was 0.5% of that to fibronectin . Isolated CD44 inhibited
binding ofKCA cells both to fibronectin and heparin-binding
peptides, but not toCSIpeptide (Fig . 8) . Binding to heparin-
binding peptides PI and PII was inhibited70% and 76%, re-
spectively, when 10 hg/ml ofCD44 was used but binding to
fibronectin was inhibited only 38 %, indicating that also
other cell surface proteins mediate KCA binding to fibro-
nectin . This was confirmed by using a polyclonal antibody
against /31 integrin that inhibited binding by 59% (Fig . 8) .
Anti-01 also inhibited binding of KCA to CSI but not com-
pletely. Partial inhibition by anti-(31 together with low ex-
pression ofa4 suggest that binding of KCA toCSImay also
involve molecules other than a4//31 . Chondroitinase treat-
ment ofKCA as well as heparin present during the adherence
assay also inhibited binding ofthese cells both to fibronectin
and heparin-binding peptides but not to the CSI peptide (Fig .
8), further supporting the involvement of glycosaminogly-
cans in the binding ofKCA to fibronectin . Inhibition percent-
82 1Figure S . Ability of different forms of lymphocyte CD44 antigen
to bind fibronectin . CD44 antigen was fractionated to yield differ-
ent forms of the molecule. Lane 1 contains the 90-kD form of the
antigen . Lane 2 contains the 180-200-kD chondroitin sulfate-con-
taining form of theCD44 antigen and its spontaneous degradation
product (90 kD) . The fibronectin binding properties of the material
on each lane was tested using an ELISA assay. The ELISA absor-
bance values (means of two analyses) are given below the corre-
sponding lanes .
ages by soluble chondroitin sulfate were clearly lower than
by heparin (Fig. 8) . Good inhibitory activity of exogenous
heparin, and poor inhibitory capacity of chondroitin sulfate
as free polysaccharide has been reported earlier (Ruoslahti,
1988; McCarthy etal ., 1990) . mAbs Hermes-1 and Hermes-3
and polyclonal anti-CD44 did not have any effecton the bind-
ing. This further suggests that chondroitin sulfate side chains
are critical in mediating binding of CD44 to fibronectin .
Discussion
In this work, we have demonstrated that lymphocyte CD44
antigen involved in lymphocyte binding to HEV also inter-
acts with extracellular matrix molecules . Moreover, these di-
verse abilities seem to be mediated through distinct struc-
tural domains of the molecule. These results, together with
the recently observed identity between CD44, hyaluronate
receptor (Aruffo et al., 1990), and collagen-binding ex-
tracellular matrix receptor type III (Carter and Wayner,
1988 ; Gallatin et al ., 1989) indicate a broad role for CD44
molecules in cell adhesion . Similarly, other homing-
associated molecules are multifunctional . LFA1 has been
described to have an accessory function in lymphocyte bind-
ing to HEV in addition to its participationin several adhesive
interactions (Hamann et al., 1988 ; Pals et al., 1988) . Yet,
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Figure 6. Heparin, heparan sulfate, chondroitin sulfate, and synde-
can inhibit CD44 antigen binding to fibronectin (10 )g/ml coating) .
Results are presented as percentages from control binding with
standard deviations. Results from three experiments are pooled .
another member of the integrin family, LPAM-1/VLA-4, a
mouse lymphocyte homing receptor to mucosal HEV, may
have other functions as well (Holzmann et al., 1989) . Re-
cently, humanVLA-4 has been shown to be involved in lym-
phocyte binding to mucosal HEV (Holzmann and Weiss-
man, 1989) ; and it has also been shown to bind fibronectin
(Wayner et al ., 1989 ; Guan and Hynes, 1990 ; for review see
Hemler et al ., 1990) . Apparentinvolvement of several struc-
turally unrelated multifunctional adhesion molecules in lym-
phocyte binding to HEV and to extracellular matrix mole-
cules demonstrates the complexity ofmechanisms regulating
lymphocyte recirculation, migration, and maturation .
SpecificityoftheCD44 AntigenBinding to FIbronectin
Acommon functional feature ofproteoglycans is the interac-
tion with extracellular matrix molecules (Ruoslahti, 1988,
1989) . Indeed, the interactions of proteoglycans with fibro-
TableI . Inhibition ofIsolated CD44AntigenBinding to the
COOH-TerminalHeparinBindingFragment ofFibronectin
822
Inhibitor Amount
Percent
Expt 1
of inhibition
Expt 2
Wglml
Chondroitin sulfate 0.5 0 ND
5 14 ND
50 69 ND
Syndecan 0.5 0 0
5 78 17
50 100 97
RGDS 5 0 0
50 0 0V
7
z
U
.1
_cc
0)
a:
100
50
100
100
100
50
100
so
0
Fluorescein
Figure 7. Expression of VLA-4a, VLA-5a, (31, and CD44 (stained
with mAb Hermes-3) on KCA cells used for inhibition studies. In-
direct immunofluorescence was carried out as described in Materi-
als and Methods. Negative control stainings were done with irrele-
vant mAb and normal rabbit serumas first stagereagents followed
by the appropriate second stage reagents. Both negative controls
gave similar results.
nectin involving heparan sulfate chains have been described
in several studies (see Saunders and Bernfield, 1988, and ref-
erences therein). Interactions of proteoglycans involving
chondroitin sulfate chains have also been observed (Ruo-
slahti, 1988; Yamagata et al ., 1986 ; Oldberg and Ruoslahti,
1982; Hedman et al., 1982; Smith, 1985). Isolated lympho-
cyte CD44 antigen bound reproducibly to the heparin-bind-
ing domain of fibronectin. This is in agreement with the
finding that the chondroitin sulfate-containing form of the
lymphocyte CD44 antigen showed significant binding to
fibronectin.
Free-sulfated polysaccharides, such as heparan sulfate and
Jalkanen and Jalkanen CD44 Binds to Fibronectin
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Figure 8. Inhibition of binding of a B lymphoblastoid cell line,
KCA, to fibronectin and fibronectin peptides (P1, Pll, and PHI).
PI and PII are heparin binding peptides (PI = KNNQKSEPLIGR-
KKT, PII = YEKPGSPPREWPRPRPGV) and PE[[ is CSI. Con-
trolbinding for mAb inhibition was the binding of cells treated with
class-matched irrelevant mAbs. Binding of cells treated with nor-
mal rabbit serum and normal mouse serum served as control bind-
ing forcells treated withpolyclonal anti-,B 1 and anti-CD44, respec-
tively. Control binding for heparin (500 FAg/ml), chondroitin sulfate
(500 Wg/ml), and CD44 inhibition was counted from wells in which
no inhibitor was present. Results are presented aspercentages from
control binding with theirstandard errors. Results from two experi-
ments are pooled.
chondroitin sulfate, bind poorly to extracellular matrix. As
a part of a proteoglycan in multivalent arrangement, how-
ever, they can interact with ligand molecules such as fibro-
nectin (Ruoslahti, 1988). This explains the partial inhibition
of binding of both isolated CD44 and KCA lymphoblastoid
cells to fibronectin by free sulfated carbohydrates in our as-
says. On the other hand, CD44 antigen may have another
binding site independent of chondroitin sulfate. This latter
possibility is, perhaps, less likely, because polyclonal and
mAbs against CD44 could not inhibit binding of KCA to
fibronectin peptides. Moreover, syndecan, which binds to
fibronectin via heparan sulfate side chains (Saunders and
Bernfield, 1988), almost completely inhibited CD44 antigen
binding. Isolated mouse and human syndecan have been re-
ported to have relatively moderate affinity to fibronectin
(Saunders and Bernfield, 1988; Elenius et al., 1990). If we
assume that syndecan and CD44 are competing for the same
binding site, the concentrations needed to inhibit the binding
of the CD44 antigen suggest a relatively high affinity for
CD44 antigen binding. However, affinities of purified anti-
gens in vitro need not necessarily reflect the situation in vivo,
wherecomplicated interactions can take place. These inhibi-
tion studies, together with the binding studies using different
forms of CD44 antigen (Fig. 5) suggest that CD44 antigen
binds to fibronectin via its chondroitin sulfate side chainsand further, that the binding site is the same as that for hepa-
rin or heparan sulfate. This conclusion is also supported by
the experiments where CD44 bound to the peptides earlier
shown to mediate heparin binding to the COOH-terminal
domain of fibronectin. Involvement of these peptides in pro-
moting the binding of CD44 suggests that the binding may
be mediated via a noncontiguous determinant in the 000H-
terminal region of the molecule. The possibility, however,
remains that CD44 also binds to the NH2-terminal heparin-
binding domain. In that case, interaction with the N112-ter-
minal region is of low affinity, because syndecan that binds
to the COOH-terminal region was able to inhibit the binding
of CD44 almost completely.
Despite common properties, fibronectins from different
sources exhibit molecular heterogeneity in terms of solubil-
ity and subunit structure because of alternative splicing
(ffrench-Constant et al., 1989) . Thus, fibronectin in lymph
nodes where it forms an intricate network throughoutthe tis-
sue except in follicles (D'Ardenne et al ., 1983), may have
different functional properties than, for example, fibronectin
found on the surfaces of vascular endothelial cells. In our
assays, soluble fibronectin did not inhibit CD44 antigen bind-
ing to immobilized fibronectin indicating that some confor-
mational changes occurring in anchored fibronectin mole-
cule are required to support thebinding ofthe CD44 antigen.
On the basis of these results, it seems likely that in vivo re-
circulating lymphocytes do not use CD44 antigen to interact
with fibronectin while still in the blood circulation. Rather,
this interaction takes place inside the lymphatic tissues. In this
regard, it is noteworthy that only a small subset of lympho-
cyte CD44 antigen isolated from PBL has covalently linked
chondroitin sulfate side chains. It is not currently known
whether certain peripheral blood lymphocytes have chon-
droitin sulfate-containing form of the CD44 antigen while
other express only the 90-kD form, or whether each cell has
both forms ofthe molecule. However, it is theoretically pos-
sible that lymphocytes with the chondroitin sulfate-contain-
ing form of the CD44 antigen represent a functionally unique
subset of lymphocytes. Several cell types of hematopoietic
origin have been shown to use VLA-5 or VLA-4 or both to
bind fibronectin (Wayner et al., 1989; for review see Shimizu
et al., 1990). In this work we have shown that a lymphoid
cell linecan also use CD44 molecule for binding to fibronec-
tin. Perhaps, CD44 is not the primary adhesion receptor to
fibronectinin a similar fashion as VLA-4 and VLA-5 but may
serve as an additional binding site for lymphocytes at certain
stages of their maturation and differentiation. Localization
of CD44 to filopodia that are involved in cell-substratum
contacts also supports the involvement of CD44 in binding
to fibronectin (Brown et al ., 1991; Jalkanen et al., 1991).
Thus, lymphocyte binding may occur as a result of interac-
tions between several surface molecules and different deter-
minants of fibronectin . Several adhesion sites have already
been shown to mediate adhesion of melanoma cells. Adhe-
sion sites for melanoma cellsinclude the same heparin-bind-
ing peptides as used in this study, RGD-containing region,
and the CSI segment (McCarthy et al., 1988, 1990) . It is ob-
vious that involvement of several molecules increases the
possibilities of regulation of cell adhesion to fibronectin.
Binding Domains ofthe CD44Antigen toHEV
andNbronectin AreSeparate
Our results clearly indicate that the binding domains of lym-
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phocyte CD44 antigen to HEV and fibronectin reside on
different parts of the molecule. The removal of chondroitin
sulfate from lymphocytes or the addition of chondroitin sul-
fate into the HEVbinding assay, had no influence on lympho-
cyte binding to HEV In contrast, Hermes-3 mAb inhibits
lymphocyte binding to mucosal HEV (Jalkanen, S., et al .,
1987) indicating that the region recognized by this antibody
is involved in the interaction between lymphocytes and en-
dothelium. Therefore, the glycosaminoglycan-containing re-
gion must be different from the HEVrecognition region . On
the other hand, chondroitin sulfate chains are needed for
fibronectin binding, and this binding is not inhibited by
mAbs (Hermes series) against different epitopes of CD44.
Furthermore, the polyclonal antibody against CD44 could
not inhibit lymphocyte binding to fibronectin. This can be
explained by the fact that the antibody does not contain any
activity against native chondroitin sulfate side chains as a
part of CD44. These results nicely demonstrate the separa-
tion of these two binding capabilities of the lymphocyte
CD44 antigen.
The ability of CD44 antigen to interact with matrix com-
ponents inside the lymphatic tissue may be essential for lym-
phocytes after leaving the vasculature. In fact, communica-
tion between lymphocytes and matrix may direct migration
and localization inside the tissue. Tissue localization, on the
other hand, may be intimately involved in the further
differentiation and maturation of lymphocytes. Moreover,
retention time inside the tissue mightbe determined by inter-
actions between recirculating lymphocytes and matrix mole-
cules. Furthermore, the ability to interact with endothelium,
enter into, and attach to the tissue are characteristics that are
important in determining the metastatic potential of lym-
phoid, as well as other malignancies. SinceCD44 molecules
are apparently involved in cell-endothelium and cell-matrix
interaction, this class of molecules may eventually serve as
useful prediction markers and, ultimately, elements critical
to the understanding of tumor invasiveness.
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